Salvadori M, Holzer H, de Mattos A, et al; on behalf of the ERL B301 Study Groups. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant. 2004;4(2):231-236.

Myfortic [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2008.

Budde K, Curtis J, Knoll G, et al; on behalf of the ERL B302 Study Group. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant. 2004;4(2):237-243.

Budde K, Knoll G, Curtis J, et al; on behalf of the ERL B302 Study Group. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic®). Clin Nephrol. 2006;66(2):103-111.

Approved Drug Products With Therapeutic Equivalence Evaluations. Center for Drug Evaluation and Research Web site.
http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm. Current through May 2009. Accessed June 18, 2009.